PERSKY MARLA
Known title: DirectorCIK: 0001270354
PERSKY MARLA's purchase track record
PERSKY MARLA has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/14/2023 | XERS | $10K | +84.0% | +21.8% | +16.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| XERS | ▲ Buy | Grant | 24,193 | $0 | 6/4/2026 | View on chart |
| XERS | ▼ Sell | Open Market | 15,500 | $91K | 6/3/2026 | View on chart |
| XERS | ▼ Sell | Open Market | 15,500 | $120K | 9/11/2025 | View on chart |
| XERS | ▲ Buy | Grant | 50,000 | $0 | 6/4/2025 | View on chart |
| XERS | ▲ Buy | Grant | 50,000 | $0 | 6/5/2024 | View on chart |
| XERS | ▲ Buy | Open Market | 6,370 | $10K | 11/14/2023 | View on chart |
| XERS | ▲ Buy | Grant | 42,500 | $0 | 6/7/2023 | View on chart |
| XERS | ▲ Buy | Grant | 15,000 | $0 | 6/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
XERS Amid Biotech Rally on Wednesday
Benzinga reported a rise in several biotech names, including TriSalus Life Sciences, Lakefront Biotherapeutics, and Editas Medicine, on Wednesday. The lift in the sector may lift XERS as well, given its position in the biotech space. XERS trades near the middle of its 52‑week range and sits above its 11‑day support at $6.17. The recent rally could provide a backdrop for further upside.
XERS Amid Biotech Rally on Wednesday. Benzinga reported a rise in several biotech names, including TriSalus Life Sciences, Lakefront Biotherapeutics, and Editas Medicine, on Wednesday. The lift in the sector may lift XERS as well, given its position in the biotech space. XERS trades near the middle of its 52‑week range and sits above its 11‑day support at $6.17. The recent rally could provide a backdrop for further upside.